References
Key articles
Weinreb RN, Leung CK, Crowston JG, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016 Sep 22;2:16067. Abstract
International Council of Ophthalmology. ICO guidelines for glaucoma eye care. Feb 2016 [internet publication].Full text
American Academy of Ophthalmology. Primary open-angle glaucoma preferred practice pattern. Nov 2020 [internet publication].Full text
American Academy of Ophthalmology. Primary open-angle glaucoma suspect preferred practice pattern. Nov 2020 [internet publication].Full text
National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. Jan 2022 [internet publication].Full text
Reference articles
1. Weinreb RN, Leung CK, Crowston JG, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016 Sep 22;2:16067. Abstract
2. World Health Organization. World report on vision. Oct 2019 [internet publication].Full text
3. International Council of Ophthalmology. ICO guidelines for glaucoma eye care. Feb 2016 [internet publication].Full text
4. US National Eye Institute. Types of glaucoma. Sep 2021 [internet publication].Full text
5. American Academy of Ophthalmology. Primary open-angle glaucoma preferred practice pattern. Nov 2020 [internet publication].Full text
6. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):532-8.Full text Abstract
7. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991 Nov 14;325(20):1412-7.Full text Abstract
8. Varma R, Ying-Lai M, Francis BA, et al; Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004 Aug;111(8):1439-48. Abstract
9. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991 Jul 17;266(3):369-74. Abstract
10. American Academy of Ophthalmology. Primary open-angle glaucoma suspect preferred practice pattern. Nov 2020 [internet publication].Full text
11. Fingert JH, Stone EM, Sheffield VC, et al. Myocilin glaucoma. Surv Ophthalmol. 2002 Nov-Dec;47(6):547-61. Abstract
12. Fingert JH. Primary open-angle glaucoma genes. Eye (Lond). 2011 May;25(5):587-95.Full text Abstract
13. Fahy ET, Chrysostomou V, Crowston JG. Mini-review: impaired axonal transport and glaucoma. Curr Eye Res. 2016;41(3):273-83. Abstract
14. Delaney Y, Walshe TE, O'Brien C. Vasospasm in glaucoma: clinical and laboratory aspects. Optom Vis Sci. 2006 Jul;83(7):406-14. Abstract
15. Khaw PT, Shah P, Elkington AR. Glaucoma-1: diagnosis. BMJ. 2004 Jan 10;328(7431):97-9.Full text Abstract
16. Kreft D, Doblhammer G, Guthoff RF, et al. Prevalence, incidence, and risk factors of primary open-angle glaucoma - a cohort study based on longitudinal data from a German public health insurance. BMC Public Health. 2019 Jul 1;19(1):851.Full text Abstract
17. Xu L, Wang Y, Wang S, et al. High myopia and glaucoma susceptibility. The Beijing Eye Study. Ophthalmology. 2007 Feb;114(2):216-20. Abstract
18. Zhou M, Wang W, Huang W, et al. Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. PLoS One. 2014;9(8):e102972.Full text Abstract
19. Zhao D, Cho J, Kim MH, et al. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology. 2015 Jan;122(1):72-8.Full text Abstract
20. Zhao YX, Chen XW. Diabetes and risk of glaucoma: systematic review and a meta-analysis of prospective cohort studies. Int J Ophthalmol. 2017;10(9):1430-5.Full text Abstract
21. Lee AJ, Wang JJ, Kifley A, et al. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006 Jul;113(7):1069-76. Abstract
22. Tielsch JM, Katz J, Sommer A, et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995 Feb;113(2):216-21. Abstract
23. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008 Jan;115(1):85-93. Abstract
24. Leske MC, Heijl A, Hyman L, et al; EMGT Group. Predictors of long-term progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007 Nov;114(11):1965-72. Abstract
25. Sit AJ, Chen TC, Takusagawa HL, et al. Corneal hysteresis for the diagnosis of glaucoma and assessment of progression risk: a report by the American Academy of Ophthalmology. Ophthalmology. 2023 Apr;130(4):433-42.Full text Abstract
26. Wu A, Khawaja AP, Pasquale LR, et al. A review of systemic medications that may modulate the risk of glaucoma. Eye (Lond). 2020 Jan;34(1):12-28.Full text Abstract
27. Kastner A, Stuart KV, Montesano G, et al. Calcium channel blocker use and associated glaucoma and related traits among UK Biobank participants. JAMA Ophthalmol. 2023 Oct 1;141(10):956-64.Full text Abstract
28. National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. Jan 2022 [internet publication].Full text
29. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20. Abstract
30. Hollands H, Johnson D, Hollands S, et al. Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review. JAMA. 2013 May 15;309(19):2035-42. Abstract
31. Dueker DK, Singh K, Lin SC, et al. Corneal thickness measurement in the management of primary open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2007 Sep;114(9):1779-87. Abstract
32. Healey PR, Mitchell P. Presence of an optic disc notch and glaucoma. J Glaucoma. 2015 Apr-May;24(4):262-6. Abstract
33. Mitchell P, Smith W, Attebo K, et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996 Oct;103(10):1661-9. Abstract
34. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004 May 22;363(9422):1711-20. Abstract
35. Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol. 1989 May 15;107(5):453-64. Abstract
36. Quigley HA, Katz J, Derick RJ, et al. An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. Ophthalmology. 1992 Jan;99(1):19-28.Full text Abstract
37. Zimprich L, Diedrich J, Bleeker A, et al. Corneal hysteresis as a biomarker of glaucoma: current insights. Clin Ophthalmol. 2020;14:2255-64.Full text Abstract
38. Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences - The Rotterdam Study. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3309-21.Full text Abstract
39. Burr JM, Mowatt G, Hernandez R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess. 2007 Oct;11(41):iii-iv, ix-x, 1-190.Full text Abstract
40. Soh Z, Yu M, Betzler BK, et al. The global extent of undetected glaucoma in adults: a systematic review and meta-analysis. Ophthalmology. 2021 Oct;128(10):1393-404.Full text Abstract
41. Chou R, Selph S, Blazina I, et al. Screening for glaucoma in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 May 24;327(20):1998-2012.Full text Abstract
42. US Preventive Services Task Force (USPSTF). Final recommendation statement. Primary open-angle glaucoma: screening. May 2022 [internet publication].Full text
43. American Optometric Association. Comprehensive adult eye and vision examination. Jan 2023 [internet publication].Full text
44. American Academy of Ophthalmology. Glaucoma summary benchmarks-2022. Dec 2022 [internet publication].Full text
45. American Academy of Ophthalmology. Comprehensive adult medical eye evaluation preferred practice pattern. Nov 2020 [internet publication].Full text
46. American Academy of Ophthalmology. Referral of persons with possible eye diseases or injury - 2014. Apr 2014 [internet publication].Full text
47. Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005 Jul 16;331(7509):134.Full text Abstract
48. Musch DC, Gillespie BW, Niziol LM, et al. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011 Sep;118(9):1766-73. Abstract
49. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018 May;96(3):e277-84.Full text Abstract
50. Lin L, Zhao YJ, Chew PT, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014 Dec;48(12):1585-93. Abstract
51. Tang W, Zhang F, Liu K, et al. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis. Medicine (Baltimore). 2019 Jul;98(30):e16597.Full text Abstract
52. Weinreb RN, van Buskirk EM, Cherniack R, et al. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol. 1988 Aug 15;106(2):162-7. Abstract
53. Coleman AL, Robin AL, Pollack IP, et al. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol. 1990;108:1264-1267. Abstract
54. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006 Sep;124(9):1230-8. Abstract
55. Miglior S, Grunden JW, Kwok K; Xalacom/Cosopt European Study Group. Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. Eye (Lond). 2010;24:1234-1242. Abstract
56. Diestelhorst M, Larsson LI; European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006 Jan;113(1):70-6. Abstract
57. Waterman H, Evans JR, Gray TA, et al. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006132.Full text Abstract
58. Oddone F, Tanga L, Kóthy P, et al; VISIONARY Study Group. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: the VISIONARY study. Adv Ther. 2020 Apr;37(4):1436-51.Full text Abstract
59. Rolim-de-Moura CR, Paranhos A Jr, Loutfi M, et al. Laser trabeculoplasty for open-angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD003919.Full text Abstract
60. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019 Apr 13;393(10180):1505-16.Full text Abstract
61. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technol Assess. 2019 Jun;23(31):1-102.Full text Abstract
62. Wright DM, Konstantakopoulou E, Montesano G, et al; Laser in Glaucoma and Ocular Hypertension Trial (LiGHT) Study Group. Visual field outcomes from the multicenter, randomized controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT). Ophthalmology. 2020 Oct;127(10):1313-21. Abstract
63. Wong MO, Lee JW, Choy BN, et al. Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol. 2015 Jan-Feb;60(1):36-50. Abstract
64. Brown SV, Thomas JV, Simmons RJ. Laser trabeculoplasty re-treatment. Am J Ophthalmol. 1985 Jan 15;99(1):8-10. Abstract
65. Starita RJ, Fellman RL, Spaeth GL, et al. The effect of repeating full-circumference argon laser trabeculoplasty. Ophthalmic Surg. 1984 Jan;15(1):41-3. Abstract
66. Zhang L, Weizer JS, Musch DC. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. Cochrane Database Syst Rev. 2017 Feb 23;(2):CD010746.Full text Abstract
67. Zhang ML, Hirunyachote P, Jampel H. Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma. Cochrane Database Syst Rev. 2015 Jul 14;(7):CD008671.Full text Abstract
68. Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol. 2013 Dec;131(12):1573-82.Full text Abstract
69. Kuo HT, Yeh CY, Hsu AY, et al. Clinical efficacy of omidenepag isopropyl for primary open-angle glaucoma, normal tension glaucoma, or ocular hypertension: a meta-analysis. J Ocul Pharmacol Ther. 2023 Aug 9.Full text Abstract
70. Bae BJ, Kang EM, Lee SY. Cystoid macular edema associated with omidenepag isopropyl in a phakic eye with an implantable collamer lens: a case report. BMC Ophthalmol. 2023 Jul 26;23(1):334.Full text Abstract
71. Weinreb RN, Liebmann JM, Martin KR, et al. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018 Jan;27(1):7-15. Abstract
72. Canadian Agency for Drugs and Technologies in Health. Clinical review report: latanoprostene bunod (Vyzulta) (Bausch Health, Canada Inc.). Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2019.Full text Abstract
73. Serle JB, Katz LJ, McLaurin E, et al; ROCKET-1 and ROCKET-2 Study Groups. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018 Feb;186:116-27.Full text Abstract
74. Asrani S, Robin AL, Serle JB, et al; MERCURY-1 Study Group. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019 Nov;207:248-57.Full text Abstract
75. Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020 Sep-Oct;3(5):327-38.Full text Abstract
76. Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2017 Jan 25;(1):CD006539.Full text Abstract
77. King AJ, Shah A, Nikita E, et al. Subconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma. Cochrane Database Syst Rev. 2018 Dec 16;(12):CD012742.Full text Abstract
78. Otarola F, Virgili G, Shah A, et al. Ab interno trabecular bypass surgery with Schlemm's canal microstent (Hydrus) for open angle glaucoma. Cochrane Database Syst Rev. 2020 Mar 9;3(3):CD012740.Full text Abstract
79. Wang X, Khan R, Coleman A. device-modified trabeculectomy for glaucoma. Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010472.Full text Abstract
80. Hu K, Shah A, Virgili G, et al. Ab interno trabecular bypass surgery with Trabectome for open-angle glaucoma. Cochrane Database Syst Rev. 2021 Feb 4;(2):CD011693.Full text Abstract
81. Augustinus CJ, Zeyen T. The effect of phacoemulsification and combined phaco/glaucoma procedures on the intraocular pressure in open-angle glaucoma. A review of the literature. Bull Soc Belge Ophtalmol. 2012;(320):51-66.Full text Abstract
82. Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol. 2016 Apr 26;10:757-64.Full text Abstract
83. Brandt JD, DuBiner HB, Benza R, et al. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmology. 2017 Oct;124(10):1565-6.Full text Abstract
84. Gote V, Sikder S, Sicotte J, et al. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019 Sep;370(3):602-24.Full text Abstract
85. Wong TT, Novack GD, Natarajan JV, et al. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv Transl Res. 2014 Aug;4(4):303-9. Abstract
86. Gutiérrez-Hernández JC, Caffey S, Abdallah W, et al. One-year feasibility study of Replenish MicroPump for intravitreal drug delivery: a pilot study. Transl Vis Sci Technol. 2014 July;3(4):1.Full text Abstract
87. Craven ER, Walters T, Christie WC, et al. 24-month phase I/II clinical trial of bimatoprost sustained-release implant (Bimatoprost SR) in glaucoma patients. Drugs. 2020 Feb;80(2):167-79.Full text Abstract
88. Dick HB, Schultz T, Gerste RD. Miniaturization in glaucoma monitoring and treatment: a review of new technologies that require a minimal surgical approach. Ophthalmol Ther. 2019 Mar;8(1):19-30.Full text Abstract
89. Jackson ML, Virgili G, Shepherd JD, et al. Vision rehabilitation preferred practice pattern®. Ophthalmology. 2023 Mar;130(3):P271-335.Full text Abstract
90. National Institute for Health and Care Excellence. Clinical knowledge summaries. Glaucoma: what is the prognosis? Feb 2023 [internet publication].Full text
Use of this content is subject to our disclaimer